From discovery to intermediates, APIs & drug products, a CDMO needs expertise across multiple elements of the pharma process to deliver an integrated experience
Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
ProBioGen is conducting cell line development, process development and GMP manufacturing of the mAb intermediates of Heidelberg’s ATAC molecules for cancer.
To increase small molecule manufacturing capacity for additional scale-up of CleanCap messenger RNA capping technology for vaccine and therapeutic programs.
Join us for a webinar on 8/18 to learn how Ology Biosciences is leveraging innovative technologies and expertise to bring vaccine production to the next level.
Dr. Ural of Ernst & Young LLP discusses market dynamics, enduring therapeutic areas, near term M&A, and how industry can use this time for transformation